4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Clinuvel Pharmaceuticals Limited (CUVL) operates in the Biotechnology industry and is headquartered in Melbourne, Australia. Its market capitalization is roughly $329 million. In the fiscal year ended 2026-06-30, CUVL reported AUD 94M in revenue and AUD 34M in net income.
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally.
Interactive charts & full statements → Open the CUVL valuation workbench →
| Income statement | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Revenue | AUD 94M | AUD 95M | AUD 88M | AUD 78M | — |
| Gross Profit | AUD 78M | AUD 79M | AUD 78M | AUD 70M | — |
| Operating Income (EBIT) | AUD 40M | AUD 46M | AUD 48M | AUD 44M | — |
| Net Income | AUD 34M | AUD 36M | AUD 36M | AUD 31M | — |
AUD; AUDM / AUDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Dividends Paid | (AUD 2M) | (AUD 2M) | (AUD 2M) | (AUD 2M) |
AUD; AUDM / AUDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Assets | AUD 295M | AUD 272M | AUD 231M | AUD 194M | — |
| Total Liabilities | AUD 22M | AUD 31M | AUD 28M | AUD 29M | — |
AUD; AUDM / AUDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CUVL viewer.
About TickerBase · Data methodology & sources · Privacy · Terms